CardioRenal Systems Inc. (RenalGuard)
Ilya Budik currently serves as the CEO of CardioRenal Systems Inc. (RenalGuard), a company developing clinically validated solutions for preventing Acute Kidney Injury (AKI), with a device approved for use in EMEA and designated as breakthrough by the FDA. Additionally, Ilya is a Managing Partner at Imagine Bio, advising healthcare leaders on strategy and investments. Previously, Ilya was the CEO of NeuroQuest, leading the development of diagnostic tests for Alzheimer’s and ALS, and contributed to business development at MND Diagnostic Ltd. Ilya's early career included roles in global finance at Ethicon Endo-Surgery and research positions at Miami University and The Ohio State University. Educational background includes degrees in Finance and Biochemistry from Miami University and specialized training in Healthcare Entrepreneurship from Tel Aviv University.
This person is not in any teams
CardioRenal Systems Inc. (RenalGuard)
CardioRenal Systems, Inc. has developed the only clinically validated solution to the biggest problem today in cardiac surgery and the ICU – Acute Kidney Injury. The technology was granted Breakthrough Designation by the FDA and is CE approved with growing adoption across Europe and the Middle East. The technology was granted Breakthrough Designation by the FDA and is CE approved with growing adoption across Europe and the Middle East.